688373 盟科药业
已收盘 04-29 15:00:01
资讯
新帖
简况
盟科药业(688373)3月31日股东户数1.7万户，较上期增加3.55%
证券之星 · 04-29 17:43
盟科药业(688373)3月31日股东户数1.7万户，较上期增加3.55%
图解盟科药业一季报：第一季度单季净利润同比增长65.19%
证券之星 · 04-29 04:54
图解盟科药业一季报：第一季度单季净利润同比增长65.19%
每周股票复盘：盟科药业（688373）完成注册资本变更
证券之星 · 04-26
每周股票复盘：盟科药业（688373）完成注册资本变更
盟科药业（688373）披露完成工商变更登记并换发营业执照公告，4月24日股价上涨0.34%
证券之星 · 04-24
盟科药业（688373）披露完成工商变更登记并换发营业执照公告，4月24日股价上涨0.34%
盟科药业（688373）2025年年报简析：营收上升亏损收窄，盈利能力上升
证券之星 · 03-29
盟科药业（688373）2025年年报简析：营收上升亏损收窄，盈利能力上升
盟科药业（688373）披露部分募集资金投资项目延期公告，3月27日股价上涨4.42%
证券之星 · 03-27
盟科药业（688373）披露部分募集资金投资项目延期公告，3月27日股价上涨4.42%
盟科药业(688373.SH)发布2025年度业绩，实现营收1.42亿元，同比增长8.83%
智通财经 · 03-27
盟科药业(688373.SH)发布2025年度业绩，实现营收1.42亿元，同比增长8.83%
每周股票复盘：盟科药业（688373）2025年净亏2.416亿同比收窄45.18%
证券之星 · 03-01
每周股票复盘：盟科药业（688373）2025年净亏2.416亿同比收窄45.18%
盟科药业：一款产品撑起上市公司，研发高投入难掩经营困局
新浪证券 · 02-28
盟科药业：一款产品撑起上市公司，研发高投入难掩经营困局
盟科药业（688373）披露2026年第一次临时股东会决议公告，2月27日股价上涨0.8%
证券之星 · 02-27
盟科药业（688373）披露2026年第一次临时股东会决议公告，2月27日股价上涨0.8%
盟科药业发布2025年度业绩快报，亏损2.416亿元
证券之星 · 02-26
盟科药业发布2025年度业绩快报，亏损2.416亿元
每周股票复盘：盟科药业（688373）MRX-5获美临床试验许可
证券之星 · 02-01
每周股票复盘：盟科药业（688373）MRX-5获美临床试验许可
盟科药业：MRX-5片获美国FDA批准开展临床试验
证券之星 · 01-28
盟科药业：MRX-5片获美国FDA批准开展临床试验
每周股票复盘：盟科药业（688373）预计2025年亏损收窄至2.25亿至2.65亿元
证券之星 · 01-25
每周股票复盘：盟科药业（688373）预计2025年亏损收窄至2.25亿至2.65亿元
盟科药业（688373）披露2025年年度业绩预告，1月23日股价上涨1.86%
证券之星 · 01-23
盟科药业（688373）披露2025年年度业绩预告，1月23日股价上涨1.86%
盟科药业（688373）披露股东减持股份计划公告，1月14日股价上涨0.45%
证券之星 · 01-14
盟科药业（688373）披露股东减持股份计划公告，1月14日股价上涨0.45%
盟科药业（688373.SH）聘任卢亮为副总经理、郭萃为财务负责人
中金财经 · 01-14
盟科药业（688373.SH）聘任卢亮为副总经理、郭萃为财务负责人
盟科药业（688373）变更证券事务代表，奉竹女士接任
中金财经 · 01-14
盟科药业（688373）变更证券事务代表，奉竹女士接任
盟科药业拟补选王星海为董事 完善公司治理结构
中金财经 · 01-14
盟科药业拟补选王星海为董事 完善公司治理结构
盟科药业（688373）披露2023年限制性股票激励计划部分归属期符合归属条件，1月13日股价上涨0.3%
证券之星 · 01-13
盟科药业（688373）披露2023年限制性股票激励计划部分归属期符合归属条件，1月13日股价上涨0.3%
加载更多
公司概况
公司名称：
上海盟科药业股份有限公司
所属行业：
医药制造业
上市日期：
2022-08-05
主营业务：
上海盟科药业股份有限公司的主营业务是以小分子化药研发为核心，发现、开发和商业化未满足临床需求的创新药物。公司的主要产品是康替唑胺片。
发行价格：
8.16
{"stockData":{"symbol":"688373","market":"SH","secType":"STK","nameCN":"盟科药业","latestPrice":5.97,"timestamp":1777446001000,"preClose":5.88,"halted":0,"volume":8943917,"delay":0,"changeRate":0.0153,"floatShares":606000000,"shares":656000000,"eps":-0.307,"marketStatus":"已收盘","change":0.09,"latestTime":"04-29 15:00:01","open":5.89,"high":6.05,"low":5.85,"amount":53481700,"amplitude":0.034,"askPrice":5.98,"askSize":576,"bidPrice":5.97,"bidSize":262,"shortable":0,"etf":0,"ttmEps":-0.307,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777512600000},"marketStatusCode":5,"adr":0,"adjPreClose":5.88,"symbolType":"stock_kcb","openAndCloseTimeList":[[1777426200000,1777433400000],[1777438800000,1777446000000]],"highLimit":6.47,"lowLimit":5.29,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":656228380,"isCdr":false,"pbRate":21.53,"roa":"--","roe":"--","epsLYR":-0.37,"committee":-0.502758,"marketValue":3918000000,"turnoverRate":0.0148,"status":0,"afterMarket":{"amount":0,"volume":0,"close":5.97,"buyVolume":0,"sellVolume":400,"time":1777448037558,"indexStatus":"已收盘 04-29 15:30:00","preClose":5.88},"floatMarketCap":3616000000},"requestUrl":"/m/hq/s/688373","defaultTab":"news","newsList":[{"id":"2631596358","title":"盟科药业(688373)3月31日股东户数1.7万户，较上期增加3.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631596358","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631596358?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:43","pubTimestamp":1777455823,"startTime":"0","endTime":"0","summary":"证券之星消息，近日盟科药业披露，截至2026年3月31日公司股东户数为1.7万户，较2月28日增加583.0户，增幅为3.55%。在化学制药行业个股中，盟科药业股东户数低于行业平均水平，截至3月31日，化学制药行业平均股东户数为3.6万户。从股价来看，2026年2月28日至2026年3月31日，盟科药业区间跌幅为2.37%，在此期间股东户数增加583.0户，增幅为3.55%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900055457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631753914","title":"图解盟科药业一季报：第一季度单季净利润同比增长65.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631753914","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631753914?lang=zh_cn&edition=full","pubTime":"2026-04-29 04:54","pubTimestamp":1777409641,"startTime":"0","endTime":"0","summary":"证券之星消息，盟科药业2026年一季报显示，一季度公司主营收入4205.97万元，同比上升26.62%；归母净利润-2145.36万元，同比上升65.19%；扣非净利润-2328.82万元，同比上升63.21%；负债率73.15%，财务费用365.38万元，毛利率85.6%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900010686.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630258802","title":"每周股票复盘：盟科药业（688373）完成注册资本变更","url":"https://stock-news.laohu8.com/highlight/detail?id=2630258802","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630258802?lang=zh_cn&edition=full","pubTime":"2026-04-26 05:24","pubTimestamp":1777152255,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，盟科药业报收于5.91元，较上周的6.21元下跌4.83%。本周，盟科药业4月20日盘中最高价报6.33元。本周关注点公司公告汇总：盟科药业完成注册资本变更，新注册资本为65622.8380万元。公司公告汇总上海盟科药业股份有限公司于2026年3月26日召开第二届董事会第二十六次会议，审议通过变更公司注册资本、修订《公司章程》并办理工商变更登记的议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600002344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629684058","title":"盟科药业（688373）披露完成工商变更登记并换发营业执照公告，4月24日股价上涨0.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629684058","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629684058?lang=zh_cn&edition=full","pubTime":"2026-04-24 22:18","pubTimestamp":1777040330,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，盟科药业报收于5.91元，较前一交易日上涨0.34%，最新总市值为38.78亿元。近日，上海盟科药业股份有限公司发布《关于完成工商变更登记并换发营业执照的公告》。公告显示，公司于2026年3月26日召开第二届董事会第二十六次会议，审议通过变更公司注册资本、修订《公司章程》并办理工商变更登记的议案。公司已办理完成相关工商变更登记和备案手续，并取得上海市市场监督管理局换发的《营业执照》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400064893.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623335061","title":"盟科药业（688373）2025年年报简析：营收上升亏损收窄，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2623335061","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623335061?lang=zh_cn&edition=full","pubTime":"2026-03-29 06:15","pubTimestamp":1774736147,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期盟科药业发布2025年年报。截至本报告期末，公司营业总收入1.42亿元，同比上升8.83%，归母净利润-2.42亿元，同比上升45.18%。本报告期盟科药业盈利能力上升，毛利率同比增幅2.43%，净利率同比增幅49.62%。证券之星价投圈财报分析工具显示：业务评价：去年的净利率为-170.42%，算上全部成本后，公司产品或服务的附加值不高。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900001610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622786798","title":"盟科药业（688373）披露部分募集资金投资项目延期公告，3月27日股价上涨4.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622786798","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622786798?lang=zh_cn&edition=full","pubTime":"2026-03-27 22:33","pubTimestamp":1774621996,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，盟科药业报收于6.14元，较前一交易日上涨4.42%，最新总市值为40.29亿元。该股当日开盘5.88元，最高6.15元，最低5.85元，成交额达6640万元，换手率为1.81%。近日，上海盟科药业股份有限公司发布《关于部分募集资金投资项目延期的公告》。公告显示，公司拟将首次公开发行募集资金投资项目中“创新药研发项目”的达到预定可使用状态日期由2026年3月调整至2027年12月。截至2025年12月31日，该项目累计投入71,858.96万元，尚需投入4,503.98万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700050335.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622941820","title":"盟科药业(688373.SH)发布2025年度业绩，实现营收1.42亿元，同比增长8.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622941820","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622941820?lang=zh_cn&edition=full","pubTime":"2026-03-27 22:12","pubTimestamp":1774620772,"startTime":"0","endTime":"0","summary":"智通财经APP讯，盟科药业(688373.SH)披露2025年年度报告，报告期公司实现营收1.42亿元，同比增长8.83%;归母净利润亏损2.42亿元，同比收窄;扣非净利润亏损2.5亿元，同比收窄;基本每股收益-0.37元。报告期内，公司仍只有康替唑胺片一款产品处于商业化阶段。公司积极探索自建团队和商业分销模式相结合的市场开拓模式，由于各项合作正处于陆续全面展开的过渡阶段，主营业务收入同比实现小幅增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420974.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688373"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616909845","title":"每周股票复盘：盟科药业（688373）2025年净亏2.416亿同比收窄45.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616909845","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616909845?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:57","pubTimestamp":1772305028,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，盟科药业报收于6.33元，较上周的6.28元上涨0.8%。本周，盟科药业2月24日盘中最高价报6.4元。本周关注点业绩披露要点：盟科药业2025年净亏2.416亿元，同比收窄45.18%。业绩披露要点盟科药业近日即将发布2025年年报，根据2月26日发布的业绩快报，归属净利润亏损2.416亿元，同比增长45.18%。上海盟科药业股份有限公司发布2025年度业绩快报，营业总收入14,177.27万元，同比增长8.83%；归属于母公司所有者的净利润为-24,161.24万元，亏损同比收窄45.18%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100001092.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614813183","title":"盟科药业：一款产品撑起上市公司，研发高投入难掩经营困局","url":"https://stock-news.laohu8.com/highlight/detail?id=2614813183","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614813183?lang=zh_cn&edition=full","pubTime":"2026-02-28 16:31","pubTimestamp":1772267460,"startTime":"0","endTime":"0","summary":"上市不到三年，盟科药业依然未能摆脱亏损泥潭。最新业绩快报显示，公司2025年归母净利润亏损2.42亿元，虽同比有所减亏，但这已是连续第四年交出的亏损成绩单。而比亏损更让市场担忧的，是公司过度依赖单一产品、研发烧钱不止、定增受阻、股东减持等多重压力交织下的生存困局。 对于盟科药业而言，单品依赖、研发高烧、资金紧张、股东减持等多重风险交织，已使其进入一个颇为艰难的阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-02-28/doc-inhpkhwe5916349.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688373","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614650850","title":"盟科药业（688373）披露2026年第一次临时股东会决议公告，2月27日股价上涨0.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614650850","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614650850?lang=zh_cn&edition=full","pubTime":"2026-02-27 23:25","pubTimestamp":1772205914,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，盟科药业报收于6.33元，较前一交易日上涨0.8%，最新总市值为41.54亿元。该股当日开盘6.29元，最高6.33元，最低6.25元，成交额达2607.69万元，换手率为0.69%。近日，盟科药业发布《2026年第一次临时股东会决议公告》。公告显示，公司于2026年2月27日召开2026年第一次临时股东会，审议通过了补选王星海先生为公司第二届董事会董事的议案。上海市方达律师事务所对本次会议出具法律意见，认为会议召集、召开程序及表决结果合法有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700043287.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614016632","title":"盟科药业发布2025年度业绩快报，亏损2.416亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614016632","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614016632?lang=zh_cn&edition=full","pubTime":"2026-02-26 17:12","pubTimestamp":1772097140,"startTime":"0","endTime":"0","summary":"证券之星消息，盟科药业近日即将发布2025年年报，根据2月26日发布的业绩快报，归属净利润亏损2.416亿元，同比增长45.18%。业绩快报公告中对经营业绩和财务状况情况的说明：（一）报告期的经营情况、财务情况及影响经营业绩的主要因素1、经营情况公司 2025 年度实现营业总收入 14,177.27 万元，同比增长 8.83%；实现归属于母公司所有者的净利润-24,161.24 万元，同比减少亏损 19,910.89 万元；实现归属于母公司所有者的扣除非经常性损益的净利润-25,026.54 万元，同比减少亏损 20,890.70 万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600025682.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608070396","title":"每周股票复盘：盟科药业（688373）MRX-5获美临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2608070396","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608070396?lang=zh_cn&edition=full","pubTime":"2026-02-01 03:51","pubTimestamp":1769889069,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，盟科药业报收于6.34元，较上周的6.56元下跌3.35%。本周，盟科药业1月26日盘中最高价报6.78元。本周关注点来自公司公告汇总：MRX-5片获USFDA批准在美开展IIa期临床试验。来自公司公告汇总：盟科药业完成限制性股票激励计划归属，新增622,889股股份上市。上海盟科药业股份有限公司完成2023年限制性股票激励计划首次授予部分第二个归属期及预留授予部分第一个归属期的股份登记工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100001350.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606080792","title":"盟科药业：MRX-5片获美国FDA批准开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2606080792","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606080792?lang=zh_cn&edition=full","pubTime":"2026-01-28 18:20","pubTimestamp":1769595631,"startTime":"0","endTime":"0","summary":"盟科药业(688373.SH)公告称，公司全资子公司MicuRx Pharmaceuticals, Inc.收到美国食品药品监督管理局的通知，公司自主研发的抗菌新药MRX-5片的临床试验申请已获得批准，可在美国开展临床试验。MRX-5片用于治疗脓肿分枝杆菌复合群感染引起的非空洞性肺病，属于新型治疗非结核分枝杆菌感染药物，具有良好的抗菌活性和安全性。该试验为随机、双盲、安慰剂对照、多中心IIa期研究。新药研发存在不确定性，对公司未来业务开拓和经营业绩的影响存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800032578.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606232232","title":"每周股票复盘：盟科药业（688373）预计2025年亏损收窄至2.25亿至2.65亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606232232","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606232232?lang=zh_cn&edition=full","pubTime":"2026-01-25 03:00","pubTimestamp":1769281233,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，盟科药业报收于6.56元，较上周的6.53元上涨0.46%。本周，盟科药业1月23日盘中最高价报6.57元。本周关注点业绩披露要点：盟科药业预计2025年归属净利润亏损2.25亿元至2.65亿元，同比亏损减少39.87%到48.95%。预计2025年全年营业收入为1.35亿元至1.55亿元。公司公告汇总上海盟科药业股份有限公司预计2025年年度实现营业收入约为13,500.00万元到15,500.00万元，同比增长3.63%至18.98%；归属于母公司所有者的净利润预计为-26,500.00万元到-22,500.00万元，同比亏损减少39.87%到48.95%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500000997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605409810","title":"盟科药业（688373）披露2025年年度业绩预告，1月23日股价上涨1.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605409810","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605409810?lang=zh_cn&edition=full","pubTime":"2026-01-23 22:54","pubTimestamp":1769180055,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，盟科药业报收于6.56元，较前一交易日上涨1.86%，最新总市值为43.01亿元。该股当日开盘6.43元，最高6.57元，最低6.4元，成交额达6023.9万元，换手率为1.53%。近日，上海盟科药业股份有限公司发布2025年年度业绩预告。公告显示，公司预计2025年年度实现营业收入约为13,500.00万元到15,500.00万元，同比增长3.63%至18.98%；归属于母公司所有者的净利润预计为-26,500.00万元到-22,500.00万元，同比亏损减少39.87%到48.95%。本次业绩预告未经注册会计师审计。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300043494.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603124476","title":"盟科药业（688373）披露股东减持股份计划公告，1月14日股价上涨0.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603124476","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603124476?lang=zh_cn&edition=full","pubTime":"2026-01-14 22:42","pubTimestamp":1768401734,"startTime":"0","endTime":"0","summary":"截至2026年1月14日收盘，盟科药业报收于6.75元，较前一交易日上涨0.45%，最新总市值为44.25亿元。公司近日发布公告称，截至公告披露日，Best Idea持有公司7.91%股份，JSR持有4.36%，GP TMT持有2.64%。股东Best Idea计划减持不超过公司总股本3%的股份，JSR及GP TMT作为一致行动人合计减持不超过公司总股本3%的股份，减持方式为集中竞价交易和大宗交易，减持期间为2026年2月5日至2026年5月4日，减持原因为资金需求，股份来源为IPO前取得。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400041617.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688373","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603596296","title":"盟科药业（688373.SH）聘任卢亮为副总经理、郭萃为财务负责人","url":"https://stock-news.laohu8.com/highlight/detail?id=2603596296","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603596296?lang=zh_cn&edition=full","pubTime":"2026-01-14 08:04","pubTimestamp":1768349055,"startTime":"0","endTime":"0","summary":"中访网数据 上海盟科药业股份有限公司于2026年1月12日召开第二届董事会第二十四次会议，审议通过了关于调整高级管理人员的议案。根据公司经营管理和组织调整的战略需要，董事会同意聘任卢亮先生为公司副总经理，聘任郭萃女士为公司财务负责人。卢亮先生自2016年起在公司任职，历任质量保证部经理、总监及质量总监，并曾担任公司职工代表监事、监事会主席。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260114/31939250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688373","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603659608","title":"盟科药业（688373）变更证券事务代表，奉竹女士接任","url":"https://stock-news.laohu8.com/highlight/detail?id=2603659608","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603659608?lang=zh_cn&edition=full","pubTime":"2026-01-14 08:04","pubTimestamp":1768349054,"startTime":"0","endTime":"0","summary":"中访网数据 上海盟科药业股份有限公司于2026年1月12日召开第二届董事会第二十四次会议，审议通过了变更证券事务代表的议案。原证券事务代表聂安娜女士因个人工作调整原因离任。董事会同意聘任奉竹女士为公司新任证券事务代表，任期自董事会审议通过之日起至第二届董事会任期届满之日止。奉竹女士曾任职于上海第一医药股份有限公司，担任过证券事务代表等职务，并已取得科创板董事会秘书任职培训证明。此次人事变动为公司正常人事调整，旨在保障公司董事会办公室相关工作的顺利衔接与开展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260114/31939248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","688373","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603596706","title":"盟科药业拟补选王星海为董事 完善公司治理结构","url":"https://stock-news.laohu8.com/highlight/detail?id=2603596706","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603596706?lang=zh_cn&edition=full","pubTime":"2026-01-14 08:04","pubTimestamp":1768349052,"startTime":"0","endTime":"0","summary":"中访网数据 上海盟科药业股份有限公司于2026年1月12日召开第二届董事会第二十四次会议，审议通过了关于补选公司董事的议案。董事会同意提名公司现任副总经理、高级副总裁兼首席技术官王星海先生为公司第二届董事会非独立董事候选人。 若王星海先生经股东大会选举通过，其董事任期将自股东大会审议通过之日起至公司第二届董事会届满之日止。此次董事补选旨在完善公司治理结构，保障董事会工作的连续性和稳定性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260114/31939243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","688373"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603638135","title":"盟科药业（688373）披露2023年限制性股票激励计划部分归属期符合归属条件，1月13日股价上涨0.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603638135","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603638135?lang=zh_cn&edition=full","pubTime":"2026-01-13 22:36","pubTimestamp":1768314974,"startTime":"0","endTime":"0","summary":"截至2026年1月13日收盘，盟科药业报收于6.72元，较前一交易日上涨0.3%，最新总市值为44.06亿元。该股当日开盘6.68元，最高6.86元，最低6.67元，成交额达1.24亿元，换手率为3.02%。近日，上海盟科药业股份有限公司发布公告称，2023年限制性股票激励计划首次授予部分第二个归属期及预留授予部分第一个归属期的归属条件已成就。公司2024年度营业收入为1.30亿元，IND申请受理1个，公司层面业绩考核归属系数为50%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300042512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688373"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777504110052,"stockEarnings":[{"period":"1week","weight":-0.0132},{"period":"1month","weight":-0.0371},{"period":"3month","weight":-0.0524},{"period":"6month","weight":-0.2061},{"period":"1year","weight":-0.0116},{"period":"ytd","weight":-0.0116}],"compareEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":0.047},{"period":"3month","weight":-0.0121},{"period":"6month","weight":0.0386},{"period":"1year","weight":0.2498},{"period":"ytd","weight":0.0349}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海盟科药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"17006人(较上一季度增加3.55%)","perCapita":"35613股","listingDate":"2022-08-05","address":"上海市浦东新区中国(上海)自由贸易试验区爱迪生路53号1幢1-4层101、2幢","registeredCapital":"65622万元","survey":" 上海盟科药业股份有限公司的主营业务是以小分子化药研发为核心，发现、开发和商业化未满足临床需求的创新药物。公司的主要产品是康替唑胺片。","listedPrice":8.16},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"盟科药业(688373)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供盟科药业(688373)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"盟科药业,688373,盟科药业股票,盟科药业股票老虎,盟科药业股票老虎国际,盟科药业行情,盟科药业股票行情,盟科药业股价,盟科药业股市,盟科药业股票价格,盟科药业股票交易,盟科药业股票购买,盟科药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"盟科药业(688373)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供盟科药业(688373)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}